Eqis Capital Management, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Eqis Capital Management, Inc.
- $1.17 Billion
- Q2 2024
A detailed history of Eqis Capital Management, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 1,285 shares of ALNY stock, worth $346,346. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,285Holding current value
$346,346% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
615Shares Held
108MCall Options Held
2.33MPut Options Held
2.17M-
Capital World Investors Los Angeles, CA15MShares$4.04 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.37 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.57 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.67 Billion0.28% of portfolio
-
Baillie Gifford & CO6.03MShares$1.63 Billion1.16% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.2B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...